白蛋白结合型紫杉醇联合顺铂方案治疗中晚期食管癌患者的临床效果分析  

Clinical Analysis of Albumin-bound Paclitaxel Combined with Cisplatin in the Treatment of Patients with Advanced Esophageal Cancer

作　　者：姜勇[1] 陈珏[1] 甘平[2] 崔林[1] 何学军[1] 吴兴军[1] JIANG Yong;CHEN Jue;GAN Ping;CUI Lin;HE Xue-jun;WU Xing-jun(Department of Oncology,the Second People's Hospital of Taizhou,Taizhou,Jiangsu Province,225500 China;Department of Pharmacy,the Second People's Hospital of Taizhou,Taizhou,Jiangsu Province,225500 China)

机构地区：[1]泰州市第二人民医院肿瘤科,江苏泰州225500 [2]泰州市第二人民医院药剂科,江苏泰州225500

出　　处：《系统医学》2019年第23期118-121,共4页Systems Medicine

基　　金：江苏省双创计划（苏人才办[2016]32号文）;江苏省自然科学基金面上项目（BK2018022212）

摘　　要：目的研究白蛋白结合型紫杉醇联合顺铂化疗方案治疗中晚期食管癌患者的临床疗效与价值,为临床治疗工作的顺利开展提供有价值的参考依据。方法随机将2018年1月—2019年1月该院60例中晚期食管癌患者分为实验组(30例,应用白蛋白结合型紫杉醇+顺铂化疗方案治疗)、对照组(30例,应用紫杉醇+顺铂治疗)。对比两组患者治疗前后卡氏评分、生存质量评分、临床治疗效果、平均生存时间。结果治疗前,实验组卡氏评分为(70.04±2.33)分、生存质量评分为(61.27±3.86)分,对照组卡氏评分为(70.05±2.32)分、生存质量评分为(61.25±3.85)分,组间差异无统计学意义(t=0.017、0.020,P=0.987、0.984>0.05)。治疗后,实验组卡氏评分为(79.65±4.03)分、生存质量评分为(83.57±4.41)分,对照组卡氏评分为(71.32±2.44)分、生存质量评分为(71.67±2.23)分,前者两项指标均高于后者,差异有统计学意义(t=9.685、13.189,P=0.000、0.000<0.05);实验组临床治疗总有效率为60.00%(18/30),对照组临床治疗总有效率为33.33%(10/30),实验组高于对照组,临床比较差异有统计学意义(χ^2=4.286,P=0.038<0.05);实验组平均生存时间为(10.37±2.38)个月,对照组平均生存时间为(6.15±1.65)个月,后者短于前者,组间比较差异有统计学意义(t=7.981,P=0.000<0.05)。结论临床治疗中晚期食管癌的过程中,应用白蛋白结合型紫杉醇联合顺铂化疗方案,疗效确切,且患者临床症状明显改善,可有效提高患者生存质量,延长生存时间、毒性反应少,值得推广与应用。Objective To study the clinical efficacy and value of albumin-bound paclitaxel combined with cisplatin chemotherapy in the treatment of patients with advanced esophageal cancer,and provide a valuable reference for the smooth development of clinical treatment.Methods From January 2018 to January 2019,60 patients with advanced esophageal cancer were randomly divided into experimental group(30 cases,treated with albumin-bound paclitaxel+cisplatin chemotherapy)and control group(30 cases,Treatment with paclitaxel+cisplatin).The Carr's score,quality of life score,clinical treatment effect and average survival time before and after treatment were compared between the two groups.Results Before treatment,the experimental group had a score of(70.04±2.33)points and a quality of life score of(61.27±3.86)points.The control group had a score of(70.05±2.32)points and a quality of life score of(61.25±3.85)points,the difference was statistically significant(t=0.017,0.020,P=0.987,0.984>0.05)After treatment,the experimental group had a score of(79.65±4.03)ponits and a quality of life score of(83.57±4.41)points.The control group had a score of(71.32±2.44)points and a quality of life score of(71.67±2.23)points.the difference was statistically significant(t=9.685,13.189,P=0.000,0.000<0.05);the experimental group total treatment efficiency was 60.00%(18/30),the total effective rate of clinical treatment in the control group was 33.33%(10/30),the difference was statistically significant(χ^2=4.286,P=0.038<0.05);the average survival time of the group was(10.37±2.38)months,and the average survival time of the control group was(6.15±1.65)months.The latter was shorter than the former,the difference was statistically significant(t=7.981,P=0.000<0.05).Conclusion The clinical application of albumin-bound paclitaxel combined with cisplatin chemotherapy in the treatment of advanced esophageal cancer is effective,and the clinical symptoms of patients are significantly improved,which can effectively improve the quality of life,prolong th

关 键 词：白蛋白结合型紫杉醇 顺铂 化疗方案 中晚期食管癌 临床效果 

分 类 号：R73[医药卫生—肿瘤]